<DOC>
	<DOCNO>NCT00774878</DOCNO>
	<brief_summary>The purpose study evaluate clinical activity AVE1642 combination fulvestrant fulvestrant alone term clinical benefit rate `` complete response '' , `` partial response '' `` stabilization disease '' . The additional objective evaluate safety profile AVE1642 combination fulvestrant fulvestrant alone , assess rate patient without disease progression 6 month overall progression-free survival time . An evaluation pharmacokinetics pharmacodynamics interaction AVE1642 fulvestrant also perform . The biological activity treatment assess tumor biopsy , possible The potential immunogenicity AVE1642 study</brief_summary>
	<brief_title>Study AVE1642 ( IGF-1R/CD221 ) Combination With Fulvestrant ( FaslodexÂ® ) Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer</brief_title>
	<detailed_description>The study treatment administer disease progression , unacceptable toxicity patient willingness discontinue .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal woman Aromatase inhibitor last hormonal treatment Breast adenocarcinoma positive hormone receptor Measurable disease per RECIST definition ECOG performance status ( PS ) &gt; 2 Prior exposure fulvestrant anti IGF1R compound No evidence hormonosensitivity HER 2neu positive tumor More one prior regimen chemotherapy metastatic disease The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Breast Tumors</keyword>
	<keyword>Anti IGF-1R</keyword>
	<keyword>Hormonosensitivity</keyword>
</DOC>